Welcome to our dedicated page for Jaguar Health SEC filings (Ticker: JAGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Jaguar Health, Inc. filings document a commercial-stage pharmaceutical issuer with Nasdaq-listed common stock and a focus on plant-derived gastrointestinal medicines. Recent 8-K reports cover Nasdaq continued-listing standards, bid-price and publicly held share requirements, reverse-stock-split effects, pre-funded warrant exercises, stockholders' equity considerations, and material agreements involving Napo Pharmaceuticals.
Proxy and charter filings describe stockholder votes, amendments to the company's certificate of incorporation, authorized-share changes, and governance procedures. The company's regulatory record also includes disclosures on crofelemer programs, Mytesi, Canalevia-CA1, operating and financial results, capital structure, clinical or regulatory matters, and other material events affecting the human-health and animal-health businesses.
Jaguar Health reported a sharp turnaround for the quarter ended March 31, 2026, driven by a major licensing transaction. Total revenue rose to $20.3 million from $2.2 million a year earlier, mainly from $19.0 million of license revenue under a new Mytesi and Canalevia license and supply agreement with Woodward, while product revenue declined.
The company posted net income of $8.7 million versus a $10.6 million loss in 2025, but common shareholders still saw a net loss of $7.0 million after $9.5 million of Series O preferred stock dividends and over $6.0 million of deemed preferred dividends. Cash was $7.3 million with $2.8 million in restricted cash, against total notes payable of about $33.2 million and a stockholders’ deficit of $15.8 million. Management disclosed recurring losses, a $391.1 million accumulated deficit and stated that these conditions raise substantial doubt about Jaguar’s ability to continue as a going concern over the next 12 months, even after receiving a $16.0 million upfront payment from a separate license and supply agreement.
Jaguar Health has restructured parts of two royalty financings by issuing a new class of Series Q Perpetual Preferred Stock. On May 19, 2026 it issued 500 Series Q shares to Uptown Capital in exchange for a $12,500,000 reduction in the December 2020 royalty balance and 408 Series Q shares to Streeterville Capital in exchange for a combined $10,200,000 reduction in the August 2022 royalty balance.
The Series Q Preferred Stock has a $25,000 stated value per share, no cash dividends, and accrues a 10% annual return payable in additional Series Q shares. It carries voting rights on an as-converted basis, subject to a 9.99% voting cap and a separate 9.99% beneficial ownership cap. The company may exchange Series Q into common stock at the Minimum Price, subject to trading, Nasdaq and ownership constraints, and holders have priority in liquidation up to their stated value plus accrued return.
The Certificate of Designation also imposes extensive covenants limiting new equity raises above $15,000,000, new debt repayment to these holders, capital structure changes, asset sales, reverse splits and fundamental transactions without consent of required holders, and provides default remedies including forced redemption into common stock within exchange and ownership caps.
Jaguar Health, Inc. notified the SEC it could not timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026 due to delays in obtaining and compiling required information, including material subsequent-event transactions. The company states it will file the Form 10-Q no later than the fifth calendar day following the prescribed due date.
The notification indicates all other periodic reports for the prior 12 months have been filed and that the company does not anticipate a significant change in results of operations compared with the prior-year period. The form is signed by CFO Carol Lizak.
Jaguar Health, Inc. received a decision letter from a Nasdaq Hearings Panel granting a short extension to regain compliance with Nasdaq listing rules. The company recently cured a deficiency in the minimum 500,000 Publicly Held Shares requirement after third-party investors exercised existing pre-funded warrants.
The Panel reset the timeframe for Jaguar to meet the Nasdaq Bid Price Rule, requiring a closing bid price of at least $1.00 per share for 10 consecutive business days, extending the deadline from May 15, 2026 to May 18, 2026. Jaguar is working to meet these terms but notes that failure to do so would subject the company to delisting from Nasdaq.
Jaguar Health, Inc. reports an update on its Nasdaq listing compliance following a recent reverse stock split. A 1-for-35 reverse split on April 30, 2026 left the company with approximately 401,226 publicly held common shares, below Nasdaq’s 500,000 minimum for continued listing. After certain third-party investors exercised existing pre-funded warrants on May 4, 2026, Jaguar now has 513,974 common shares issued and outstanding and 513,939 publicly held shares. The company is awaiting formal Nasdaq staff confirmation that it meets the Publicly Held Shares Requirement, and it must still later demonstrate a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days under Nasdaq Listing Rule 5810(c)(3)(A).
Jaguar Health, Inc. reported that Nasdaq staff notified the company it is out of compliance with the exchange’s listing rules following a recent reverse stock split. After a 1-for-35 reverse split of its common stock effective April 30, 2026, the company has approximately 401,226 publicly held shares.
This falls below Nasdaq Listing Rule 5550(a)(4), which requires at least 500,000 publicly held shares, creating an additional basis for potential delisting from The Nasdaq Capital Market. Jaguar must present its views on this new deficiency to the Nasdaq Hearings Panel in writing by May 8, 2026.
Nasdaq staff also noted the company remains out of compliance with the minimum $1.00 bid price requirement. If Jaguar cannot cure the publicly held shares deficiency and then demonstrate a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days, its securities may be delisted from Nasdaq.
Jaguar Health has called its 2026 annual stockholder meeting for May 22, 2026 to elect one Class II director, ratify RBSM LLP as auditor, and vote on several financing proposals.
The company is seeking approval under Nasdaq Listing Rule 5635(d) to issue more than 19.99% of its common stock to C/M Capital Master Fund through a proposed $40 million equity line of credit and a separate preferred stock financing. Jaguar plans an equity line allowing sales of common stock up to $40 million plus 2% in commitment shares, and a private placement of Series P Non-Convertible Preferred Stock with $2.4 million stated value sold for $2.0 million, along with $72,000 of commencement shares. Both structures could significantly dilute existing holders if fully utilized, though C/M Capital’s ownership would be capped at 4.99%, or 9.99% with notice.
Jaguar Health received a decision from the Nasdaq Hearings Panel allowing its shares to remain listed, provided it regains compliance with Nasdaq’s bid price rule. To do this, the company must achieve a closing bid of at least $1.00 per share for 10 consecutive business days on or before May 15, 2026.
To help reach this threshold, Jaguar is implementing a 1‑for‑35 reverse stock split of its common stock, effective April 30, 2026, with trading to continue on a split‑adjusted basis on The Nasdaq Capital Market under the symbol JAGX. Every 35 existing shares will convert into one share, with no change in par value and no fractional shares issued; cash will be paid instead of fractions.
The reverse split also proportionately adjusts outstanding options, warrants, and equity plan reserves, but does not change the total number of authorized common or preferred shares. The Panel will retain jurisdiction over Jaguar until September 1, 2026, and the company may be delisted if it fails to meet the bid price requirement or other Nasdaq rules.
Jaguar Health, Inc. is asking stockholders to approve, pursuant to Nasdaq Listing Rule 5635(d), the potential issuance of Common Stock to C/M Capital Master Fund, LP that could exceed 19.99% of shares outstanding. The proxy seeks approval for two financings: an equity line of credit to sell up to $40,000,000 of Common Stock and a private preferred-stock purchase (Series P) tied to up to $2,400,000 stated value, plus $72,000 in Commencement Shares. Shares outstanding were 14,044,277 as of April 15, 2026. The filings describe mechanics, limits (a 4.99% beneficial ownership cap, increaseable to 9.99% by notice), registration rights, dilution examples at various prices, and a board-backed proposal to allow adjournment to solicit additional proxies for these approvals.